CXCR4-Targeted 68Ga-Pentixafor PET/CT Imaging in Inflammatory Bowel Disease

Author:

Chen Yang1,Yuan Hui1,Tan Xiaoyue1,Shang Yuxiang1,Sun Xiaolin1,Wang Peng1,Jiang Lei

Affiliation:

1. PET Center, Department of Nuclear Medicine, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University

Abstract

Purpose To investigate the role of CXCR4-targeted 68Ga-pentixafor PET/CT imaging in inflammatory bowel disease (IBD). Methods Five IBD patients and 12 control subjects performing 68Ga-pentixafor PET/CT examinations were included. 68Ga-pentixafor PET/CT imaging and endoscopic findings were recorded and compared. The semiquantitative parameters of 68Ga-pentixafor uptake by the lesion segments in IBD patients and the normal intestines in the control were investigated. Results Among these 5 IBD patients, endoscopy successfully examined a total of 26 intestinal segments, with 13 segments showing endoscopic lesions. 68Ga-pentixafor PET/CT was positive in all endoscopy-proven lesions (13/13). Additionally, 68Ga-pentixafor PET/CT revealed the lesions in small intestines and colons that cannot be reached by endoscopy due to severe stenosis, and mesenteric lymphadenitis accompanied IBD. The SUVmax of the lesion segments in IBD patients was significantly higher than that of the normal intestines in the control group (median, 3.15 [range, 1.61–6.26] vs 1.67 [1.18–2.29], P < 0.001). Moreover, the SUVmax ratios of the lesion segments/liver or blood pool were higher when compared with the control (2.20 [1.13–3.26] vs 0.85 [0.54–1.20]; 1.66 [0.94–2.95] vs 0.67 [0.52–1.04]; P ≤ 0.001). Conclusion 68Ga-pentixafor PET/CT can be a potentially valuable tool to assess the active intestinal lesions of IBD with high sensitivity. Moreover, this noninvasive approach does not require fasting or bowel preparation, offering good tolerance and safety.

Publisher

Ovid Technologies (Wolters Kluwer Health)

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3